High-Purity Therapeutic Peptides & API Catalog
Explore our premium grade generic APIs and custom synthesis sequences manufactured under stringent cGMP and ISO 13485 quality standards for biopharmaceutical partners worldwide.
Executive Technical Overview: Thymosin Alpha 1 (CAS 62304-98-7)
Thymosin Alpha 1 (Tα1) is an acidic 28-amino acid polypeptide originally isolated from bovine thymic tissue (Thymosin Fraction 5) and now produced through state-of-the-art solid-phase and liquid-phase peptide synthesis (SPPS/LPPS). As an essential immunomodulatory API, Tα1 regulates cellular immunity by restoring T-cell homoeostasis and activating native immune cascades.
Molecular Structure & Chemistry
Sequence: Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn-OH
Molecular Formula: C129H215N33O55 | Molecular Weight: 3108.37 g/mol
Thymosin Alpha 1 features an N-terminal acetylation that confers enzymatic stability against exopeptidase degradation in human plasma. The peptide possesses a highly negative net charge at physiological pH due to multiple Glutamic Acid (Glu) and Aspartic Acid (Asp) residues, necessitating specialized ion-exchange chromatographic protocols during purification.
Quality Control & Analytical Specifications
At Hangzhou Thinheal Pharma-Tech, each production lot undergoes rigorous analytical characterization to comply with international pharmacopeial mandates (USP/EP/Ph. Eur.):
- Purity (RP-HPLC): ≥98.0% (Single Impurity <0.5%)
- Mass Identity (ESI-MS / MALDI-TOF): 3108.37 ± 1.0 Da
- Acetate Content (IC/HPLC): 4.0% – 12.0% w/w
- Bacterial Endotoxins (LAL Test): <0.05 EU/mg (Parenteral Grade)
- Water Content (Karl Fischer): ≤5.0%
| Parameter | Research & Development Grade | Commercial cGMP API Grade | Methodology |
|---|---|---|---|
| Appearance | White Lyophilized Powder | White to Off-White Sterile Powder | Visual Inspection |
| HPLC Purity | ≥95.0% or ≥98.0% | ≥99.0% (Ultra-Pure) | RP-HPLC (C18 Column, 214nm) |
| Mass Conformance | Conforms to Molecular Weight | Conforms to Molecular Weight | LC-MS / ESI-MS Mass Spectrometry |
| Counter-Ion | Trifluoroacetate (TFA) / Acetate | Pharmaceutically Acceptable Acetate | Ion Chromatography (IC) |
| Endotoxin Limit | <0.5 EU/mg | <0.01 EU/mg (Injectable Spec) | Chromogenic LAL Assay |
| Residual Solvents | <0.5% (TFA, Acetonitrile) | Conforms to ICH Q3C Guidelines | Headspace Gas Chromatography (HS-GC) |
Comprehensive Thymosin Alpha 1 Benefits & Molecular Mechanisms
Thymosin Alpha 1 acts as a master immunomodulator without inducing pro-inflammatory cytokine hyper-activation. It interacts directly with Toll-Like Receptors (TLR2 and TLR9) on myeloid dendritic cells and monocytes, triggering intracellular signaling pathways that reconstitute immune homeostasis.
T-Cell Maturation & CD4+/CD8+ Rebalancing
Tα1 accelerates the differentiation of bone marrow-derived stem cells into functional T-lymphocytes within the thymus gland. Clinical studies demonstrate that Tα1 upregulates Terminal Deoxynucleotidyl Transferase (TdT) activity and increases absolute CD3+, CD4+ helper T-cell, and CD8+ cytotoxic T-cell counts, effectively restoring immune function in immunocompromised states.
TLR2 / TLR9 Signaling Cascade Activation
By engaging Toll-Like Receptors TLR2 and TLR9 on plasmacytoid dendritic cells (pDCs), Thymosin Alpha 1 initiates the MyD88-dependent signal pathway. This downstream activation triggers NF-κB and IRF7 transcription factors, promoting the balanced release of Interferon-alpha (IFN-α), Interferon-gamma (IFN-γ), and Interleukin-2 (IL-2).
NK Cell Cytotoxicity & MHC-I Expression
Tα1 enhances Natural Killer (NK) cell lytic activity against virally infected cells and oncogenic lineages. Furthermore, it upregulates Major Histocompatibility Complex Class I (MHC-I) expression and beta-2 microglobulin on target cell surfaces, enhancing antigen presentation and T-cell mediated target elimination.
Suppression of Cytokine Storms & Inflammation
Crucially, Tα1 exhibits a dual protective mechanism: while boosting defensive immunity, it simultaneously mitigates hyper-inflammatory tissue damage. Tα1 induces Indoleamine 2,3-dioxygenase (IDO) expression, expanding Regulatory T-cells (Tregs: CD4+CD25+FoxP3+) to suppress pathogenic IL-6, TNF-α, and IL-1β cytokine surges.
Synergy with Immune Checkpoint Inhibitors
In modern clinical oncology, Thymosin Alpha 1 is widely investigated as an adjuvant partner. Combining Tα1 with anti-PD-1 / anti-PD-L1 monoclonal antibodies counteracts tumor-induced immunosuppression, converting "cold" tumors into immunologically active "hot" tumors with improved lymphocyte infiltration.
Reversal of Immunosenescence in Longevity Research
As human aging leads to thymic involution and a depleted naive T-cell pool, Tα1 peptide administration helps restore youthful thymic signaling. It promotes the generation of naive T-cells, enhances anti-pathogen vigilance, and improves response rates to seasonal vaccinations in geriatric models.
Macro Industry Solutions & Biopharmaceutical Integration
Thymosin Alpha 1 (CAS 62304-98-7) has transitioned from an niche thymic extract to a global strategic API utilized across multiple biopharmaceutical and clinical research domains.
1. Chronic Viral Infectious Disease Therapies
Thymosin Alpha 1 is widely approved across more than 35 countries for the clinical treatment of Chronic Hepatitis B (HBV) and Chronic Hepatitis C (HCV) as monotherapy or combined with interferon-alpha or nucleoside analogs (e.g., Entecavir, Tenofovir). Tα1 enhances viral clearance by promoting HBV-specific T-cell responses and limiting hepatic necrosis.
2. Oncology & Chemo-Radiotherapy Adjuvants
During aggressive chemotherapy or radiation protocols, patient bone marrow suppression often leads to severe lymphopenia and life-threatening opportunistic infections. Administering Tα1 counteracts chemotherapy-induced leucopenia, speeds bone marrow recovery, and preserves host immune defenses against secondary pathogens.
3. Vaccine Adjuvant Technology
Incorporating Thymosin Alpha 1 into viral and sub-unit vaccine formulations significantly boosts seroconversion rates and antibody titers. This application is vital for high-risk populations, including hemodialysis patients, cancer survivors, and elderly cohorts who display blunted immune responses to standard vaccines.
4. Advanced Anti-Aging & Anti-Sepsis Formulations
In critical care settings, Tα1 is routinely deployed to manage severe sepsis and acute respiratory distress syndromes (ARDS) by preventing lymphocyte apoptosis. Additionally, anti-aging clinic networks globally integrate custom-synthesized Tα1 into longevity protocols targeted at immunosenescence mitigation.
Global Supply Chain Dynamics & China Synthesis Excellence
The global demand for synthetic peptide APIs has expanded exponentially. As a premier peptide CDMO based in Hangzhou, China, Hangzhou Thinheal Pharma-Tech Co., Ltd. addresses global supply bottlenecks through advanced chemical synthesis platforms and multi-ton annual capacity.
Hybrid SPPS / LPPS Platform
Synthesizing a 28-amino acid sequence with high purity requires overcoming steric hindrance and peptide aggregation during coupling steps. We utilize microwave-assisted Fmoc Solid-Phase Peptide Synthesis (SPPS) for fragment assembly, combined with Liquid-Phase (LPPS) segment condensation for commercial metric-ton batches.
Purity & Yield Optimization
Utilizing high-performance C18 preparative reverse-phase liquid chromatography (RP-HPLC) with automated column switching, we achieve product purity levels exceeding 99.0%. Our proprietary trifluoroacetic acid (TFA) to acetate ion-exchange process guarantees low residual TFA levels (<0.1%), satisfying strict regulatory pharmacopeial limits.
Cost Efficiency & Bulk Pricelist Factors
Commercial bulk pricing for Thymosin Alpha 1 API is dictated by raw material scale (protected Fmoc amino acids, CTC resin), purification yields, counter-ion requirements, and batch sizes (gram-scale vs. kilogram commercial orders). Direct factory manufacturing eliminates middleman markups, yielding competitive cost advantages.
Global Regulatory Assurance & Localized Client Support
Navigating global pharmaceutical regulations demands robust documentation and localized technical assistance. Thinheal provides complete regulatory dossiers to accelerate your market entry in North America, Europe, Asia-Pacific, and the Middle East.
Regulatory Documentation Package
Every commercial lot of Thymosin Alpha 1 API is backed by a full quality file designed to support regulatory audits and investigational submissions:
- Drug Master File (DMF): Type II DMF filed with US FDA / EU CEP documentation support
- Certificate of Analysis (COA): Comprehensive HPLC, MS, IC, GC, and LAL data per batch
- Safety & Origin Certificates: MSDS, TSE/BSE-Free Certificate, Non-GMO Statement
- Stability Data: Accelerated (25°C/60% RH) and Long-Term (-20°C) stability testing protocols
Cold-Chain Supply Chain & Global Desks
Peptides are sensitive biological molecules prone to hydrolytic degradation if mismanaged during transit. Thinheal operates dedicated regional desks tailored to local market needs:
- Cold-Chain Logistics: Temperature-monitored shipping (-20°C dry ice or 2-8°C cold packs)
- Customs Clearing Assistance: Specialized pharmaceutical customs clearance in EU, USA, CIS, and LATAM
- Dedicated Regional Desks: 24/7 technical support for USA & Europe, Russia & CIS, Asia, and Middle East
Localized Application Scenarios & Formulation Guidelines
Whether formulating finished injectable biopharmaceuticals or developing custom research reagents, selecting the right physical parameters for Thymosin Alpha 1 is essential for active efficacy.
1. Parenteral Injectable Lyophilization
The standard commercial dose for Thymosin Alpha 1 is 1.6 mg subcutaneous injection (often marketed under brand names such as Zadaxin). We supply sterile bulk powder optimized for reconstituting in Bacteriostatic Water or 0.9% Normal Saline with mannitol/trehalose bulking agents.
2. Nasal & Mucosal Delivery Platforms
Biotech research entities are evaluating intranasal delivery platforms for Tα1 to bypass parenteral administration. Formulations utilize permeation enhancers (such as chitosan or cyclodextrins) to maintain peptide stability across mucosal epithelial barriers.
3. OEM/ODM Custom Formulations
We provide full-service white-label OEM/ODM solutions for clinical trial sponsors and specialized peptide distribution brands, supplying premixed lyophilized vials with custom capping, labeling, and sterile packaging.
Next-Generation Technical Roadmap & Peptide Innovations
Thinheal’s R&D division continuously explores green chemical synthesis, structural modification, and artificial intelligence models to advance peptide therapy platforms.
Green Enzymatic Peptide Ligation
Transitioning from traditional organic solvent coupling to enzymatic peptide ligation platforms, reducing hazardous waste (DMF/NMP) by up to 70% while improving atom economy.
Long-Acting PEGylated Analogues
Developing novel site-specific PEGylated and fatty-acid conjugated Thymosin Alpha 1 derivatives to extend half-life from hours to weekly dosing, dramatically improving patient compliance.
AI-Driven Peptide Folding Models
Integrating machine-learning algorithm suites to model peptide-receptor binding dynamics (TLR2/TLR9 docking), enabling rational design of ultra-potent immunomodulatory sequence variants.
Continuous Flow LPPS Automation
Pioneering automated continuous-flow liquid-phase synthesis reactors for metric-ton commercial orders, shortening production cycles from weeks to days with zero batch-to-batch variation.
Commercial Pricelist & Service Matrix
We offer transparent tier-based pricing structures for research institutes, biotech startups, and global pharmaceutical manufacturing clients. Contact our regional sales teams for customized volume quotations.
| Service Level | Target Purity | Standard Batch Scale | Lead Time | Included Deliverables |
|---|---|---|---|---|
| R&D Pilot Evaluation | ≥95.0% or ≥98.0% | 1g – 100g | 1 – 2 Weeks | COA, HPLC Chromatogram, MS Report, TFA Counter-ion |
| Clinical Trial Supply (Phase I-III) | ≥98.0% / ≥99.0% | 100g – 5kg | 2 – 4 Weeks | cGMP Batch Records, Endotoxin Testing, Acetate Exchange, Stability Data |
| Commercial Metric-Ton CDMO | ≥99.0% (Injectable) | 10kg – 1000kg+ | Scheduled Rolling Supply | Full DMF / CEP Documentation, On-Site Audit Support, Dedicated QA Manager |
Require a Custom Sequence Synthesis or Bulk Pricelist?
Connect directly with Thinheal's senior peptide synthesis engineers to review your analytical specifications, request scale-up quotes, or schedule a cGMP facility virtual tour.
Contact Our Peptide DeskFrequently Asked Questions: Technical & Sourcing Guide
Answers to key questions asked by pharmaceutical procurement officers, regulatory affairs managers, and biotech researchers during supplier qualification.
Explore More Peptide APIs & Research Ingredients
Complementary high-purity peptides engineered for gastrointestinal, metabolic, cosmetic, and regenerative therapeutic research.
